Plus BridgeBio cancer subsidiary finds SPAC route to market, in an otherwise sleepy week for fundraising

Vertex’s Nav1.8 inhibitor, Axsome’s acute migraine therapy and Daiichi-AZ’s two ADCs for breast cancer among the month’s approvals

Advice for CEOs and CFOs as they navigate the year ahead

Plus: updates on AZ, Actimed, Kailera, Nasus and more

Decisions include Ozempic for CKD, a non-opioid painkiller, AZ-Daiichi’s TROP2 ADC, and an allogeneic T cell therapy

BioCentury’s final Public Equity Report of the year tallies up fundraising activity

NewAmsterdam’s CETP readout leads to week’s largest follow-on

Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more